Altered cardiovascular regulation in arginine vasopressin-overexpressing transgenic rat

American Journal of Physiology - Endocrinology and Metabolism

Volumn 285, Issue 6 48-6, 2003, Pages

  Tachikawa, Kazushige ^a   Yokoi, Hisashi ^a   Nagasaki, Hiroshi ^a   Arima, Hiroshi ^a   Murase, Takashi ^b   Sugimura, Yoshihisa ^b   Miura, Yoshitaka ^a   Hirabayashi, Masumi ^c   Oiso, Yutaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c YS New Technology Institute Inc   (Japan)

Author keywords

Blood pressure; Desensitization; Transgenic animal

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ARGIPRESSIN; MESSENGER RNA; VASOPRESSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HEART RATE; HEMORRHAGIC HYPOTENSION; HORMONE BLOOD LEVEL; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; NORTHERN BLOTTING; PREMEDICATION; PRIORITY JOURNAL; RAT STRAIN; STATISTICAL SIGNIFICANCE; TRANSGENIC ANIMAL;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARGININE VASOPRESSIN; BLOOD PRESSURE; CAROTID ARTERY DISEASES; HEMORRHAGE; HEMOSTASIS; MALE; PIPERIDINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOPRESSIN;

EID: 0344896640     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Altura BM and Altura BT. Vascular smooth muscle and neurohypophyseal hormones. Fed Proc 36: 1853-1860, 1977.
2. Bayorh MA, Ogbolu EC, Williams E, Thierry-Palmer M, Sanford G, Emmett N, Harris-Hooker S, Socci RR, Chu TC, and Chenault VM. Possible mechanisms of salt-induced hypertension in Dahl salt-sensitive rats. Physiol Behav 65: 563-568, 1998.
3. Bennett T and Gardiner SM. Vasopressin and the cardiovascular system: physiology or pharmacology? J Cardiovasc Pharmacol 8: S44-S49, 1986.
4. Berecek KH. Role of central vasopressin in cardiovascular regulation. J Cardiovasc Pharmacol 8: S76-S80, 1986.
5. Berecek KH, Murray RD, Gross F, and Brody MJ. Vasopressin and vascular reactivity in the development of DOCA hypertension in rats with hereditary diabetes insipidus. Hypertension 4: 3-12, 1982.
6. Cowley AW Jr and Liard JF. Cardiovascular actions of vasopressin. In: Vasopressin Principles and Properties, edited by Gash DM and Boer GJ. New York: Plenum, 1987, p. 389-433.
7. Cowley AW Jr, Skelton MM, and Kurth TM. Effects of long-term vasopressin receptor stimulation on medullary blood flow and arterial pressure. Am J Physiol Regul Integr Comp Physiol 275: R1420-R1424, 1998.
8. Crofton JT, Ota M, and Share L. Role of vasopressin, the renin-angiotensin system and sex in Dahl salt-sensitive hypertension. J Hypertens 11: 1031-1038, 1993.
9. Haywood JR, Brennan TJ, and Hinojosa C. Neurohumoral mechanisms of sodium-dependent hypertension. Fed Proc 44: 2393-2399, 1985.
10. Hirasawa A, Hashimoto K, and Tsujimoto G. Distribution and developmental change of vasopressin V1A and V2 receptor mRNA in rats. Eur J Pharmacol 267: 71-75, 1994.
11. Johnson JV, Bennett GW, and Hatton R. Central and systemic effects of a vasopressin V1 antagonist on MAP recovery after haemorrhage in rats. J Cardiovasc Pharmacol 12: 405-412, 1988.
12. Kakiya S, Arima H, Yokoi H, Murase T, Yambe Y, and Oiso Y. Effects of acute hypotensive stimuli on arginine vasopressin gene transcription in the rat hypothalamus. Am J Physiol Endocrinol Metab 279: E886-E892, 2000.
13. Leaf A, Bartter FC, Santos RF, and Wrong O. Evidence in man that urinary electrolyte loss induced by pitressin is a function of water retention. J Clin Invest 32: 868-878, 1953.
14. Morel A, O'Carroll AM, Brownstein MJ, and Lolait SJ. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 356: 523-526, 1992.
15. Nagasaki H, Yokoi H, Arima H, Hirabayashi M, Ishizaki S, Tachikawa K, Murase T, Miura Y, and Oiso Y. Overexpression of vasopressin in the rat transgenic for the metallothionein-vasopressin fusion gene. J Endocrinol 173: 35-44, 2002.
16. Oiso Y, Iwasaki Y, Kondo K, Takatsuki K, and Tomita A. Effect of the opioid kappa-receptor agonist U50488H on the secretion of arginine vasopressin. Study on the mechanism of U50488H-induced diuresis. Neuroendocrinology 48: 658-662, 1988.
17. Pawloski CM, Eicker NM, Ball LM, Mangiapane ML, and Fink GD. Effect of circulating vasopressin on arterial pressure regulation in rats. Am J Physiol Heart Circ Physiol 257: H209-H218, 1989.
18. Pfeiffer R, Kirsch J, and Fahrenholz F. Agonist and antagonist-dependent internalization of the human vasopressin V2 receptor. Exp Cell Res 244: 327-339, 1998.
19. Schwartz J and Reid IA. Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs. Endocrinology 109: 1778-1780, 1981.
20. Share L. Role of vasopressin in cardiovascular regulation. Physiol Rev 68: 1248-1284, 1988.
21. Share L and Crofton JT. The role of vasopressin in hypertension. Fed Proc 43: 103-106, 1984.
22. Smith MJ Jr, Cowley MJ Jr, Guyton AC, and Manning RD Jr. Acute and chronic effects of vasopressin on blood pressure, electrolytes, and fluid volumes. Am J Physiol Renal Fluid Electrolyte Physiol 237: F232-F240, 1979.
23. Vallotton MB, Wuthrich RP, Lew PD, and Capponi AM. Effects of vasopressin and its analogs on rat aortic smooth muscle and renal medullary tubular cells: characterization of receptor subtypes. J Cardiovasc Pharmacol 8: S5-S11, 1986.
24. Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura S, Mori T, Tominaga M, and Yabuuchi Y. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 252: 572-574, 1991.
25. Yokoi H, Nagasaki H, Tachikawa K, Arima H, Murase T, Miura Y, Hirabayashi M, and Oiso Y. Adaptation to sustained high plasma vasopressin in water and electrolyte homeostasis in the rat transgenic for the metallothionein-vasopressin fusion gene. J Endocrinol 173: 23-33, 2002.
26. Zerbe RL, Bayorh MA, and Feuerstein G. Vasopressin: an essential pressor factor for blood pressure recovery following hemorrhage. Peptides 3: 509-514, 1982.
27. Zingg HH. Vasopressin and oxytocin receptors. Baillieres Clin Endocrinol Metab 10: 75-96, 1996.